NYSE:RCUSBiotechs
Arcus Biosciences Q1 Loss Of US$128 Million Reinforces Bearish Profitability Concerns
Arcus Biosciences (RCUS) opened 2026 with Q1 revenue of US$17 million and a basic EPS loss of US$1.02, alongside a net loss of US$128 million, as investors weigh how the current burn supports its pipeline progress. Over recent quarters the company has seen quarterly revenue move from US$28 million in Q1 2025 to US$160 million in Q2 2025, before settling at US$33 million in Q4 2025 and US$17 million in Q1 2026. Over the same period, EPS has ranged between a loss of US$0.89 and US$1.27 per...